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Arrhythmogenic right ventricular cardiomyopathy type 5
(ARVC-5) is a rare inherited autosomal-dominant cardiac
disorder known to cause sudden cardiac death (SCD) in
young people, mostly men and typically between second and
fourth decade of life.1–3 ARVC-5 is coupled to the p.
Ser358Leu mutation in the transmembrane protein 43 gene
(TMEM43) on chromosome 3p25 and is associated with
myocardial ﬁbrosis and progressive loss of predominantly
right ventricular (RV) tissue with ﬁbrofatty replacement,
although left ventricular (LV) involvement is not uncom-
mon.1,2,4 TMEM43 p.Ser358Leu is a fully penetrant muta-
tion. Current diagnostic criteria of ARVC require a number
of major and minor criteria, including structural and/or
functional RV abnormalities, tissue characteristics, abnor-
malities of repolarization and conduction, and arrhythmias.5
Previous studies on the TMEM43 p.S358L mutation indicate
an extremely severe phenotype where SCD commonly is the
ﬁrst symptom in high-risk patients.1,2,6,7 As carriers of the
gene mutation, patients are often offered prophylactic
implantable cardioverter-deﬁbrillator (ICD) for primary
prevention therapy, despite lack of other cardiac symptoms.8
In this report we present 3 unrelated cases with ARVC-5
due to the TMEM43 p.Ser358Leu mutation in which ICD
therapy unfortunately could not prevent SCD.
Case report
Case 1
A 57-year-old man (III-6) with ARVC diagnosed at the age
of 46 and a biventricular ICD (cardiac resynchronization
therapy device; CRT-D) owing to heart failure collapsed in a
conference room, and basic resuscitation was started imme-
diately (Figure 1, Table 1). Paramedics arrived 6 minutesKEYWORDS ARVC; Genetics; ICD; Sudden cardiac death; TMEM43
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therefore started treatment with intravenous adrenaline. In
hospital, coronary angiography was normal, and echocar-
diography showed cardiac standstill and LV dilatation of 8
cm, RV with no signiﬁcant dilatation, and no sign of
pulmonary embolism. Admitted to the intensive care unit,
the patient was declared dead less than 2 hours after cardiac
arrest. The relatives refused autopsy. A few days before
death, the index patient had been admitted to hospital with
recurrent slow ventricular tachycardia (VT), terminated by
antitachycardia pacing (ATP). The CRT-D was well func-
tioning. We have indirect evidence of endomyocardial RV
ﬁbrosis from 2 previously performed 3-dimensional electro-
anatomic maps and catheter ablation procedures for mono-
morphic VT. Further, lack of R-wave progression in
precordial leads was observed in the electrocardiogram at
patient age of 42—4 years prior to diagnosis of ARVC
(Figure 2A).
In regard to previously observed slow and fast ventricular
arrhythmias, the CRT-D (Biotronik LUMAX 540 HF-T,
Biotronik, Berlin, Germany) was programmed as follows:
VT-1 zone 162 beats per minute (bpm) (therapy: ATP6, 40
J shock 1), VT-2 zone 188 bpm (ATP 2, 40 J shock 1),
and VF zone 250 bpm (40 J shock 6). Postmortem device
interrogation showed low-amplitude ventricular ﬁbrillation
(VF) detected in VT-1 and VT-2 zones with numerous
unsuccessful ATP attempts (Figure 2B). Owing to intermit-
tent under-sensing of VF, the CRT-D delivered only 2 direct
current shocks, of which 1 converted the rhythm to short-
lasting paced rhythm before reversal to VT (Figure 2C).
Molecular genetic testing for ARVC had revealed the p.
Ser358Leu mutation in TMEM43, conﬁrming ARVC type
5 in this patient. He had a family history of SCD. Seven out
of 10 family members tested carried this mutation
(Figure 1); of those, 5 had severe cardiac symptoms, 1
with heart transplantation (HTx) at age 44 years owing to
progressive heart failure and multiple shocks from the ICD
(III-5). All 5 met the diagnostic criteria for ARVC.
Including the index case, 6 family members with a positive
genetic test have an ICD.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.12.009
KEY TEACHING POINTS
 Arrhythmogenic right ventricular cardiomyopathy
type 5 (ARVC-5), caused by the TMEM43 p.
Ser358Leu mutation, has an extremely severe
phenotype.
 Refractory low-amplitude ventricular tachycardia
(VT) or ventricular ﬁbrillation (VF) seems to be the
main reason why the implantable cardioverter-
deﬁbrillator can be unable to deﬁbrillate ARVC-5
patients.
 Heart transplant for patients with ARVC-5 with an
impact on right ventricle and/or left ventricle
function and numerous episodes of VT/VF could be
the next line of treatment to consider.
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A 27-year-old man (III-1) massively predisposed to heart
disease and SCD was found dead in his home (Figure 1).
Eight months prior to death he had the diagnosis of ARVC
and received an ICD (CPI 1715; Guidant, Indianapolis, IN)
(Table 1). One month before death an ICD control revealed 2
episodes of VT (190 bpm), with appropriate shock therapy
restoring sinus rhythm, and the ICD was found to be fully
functioning. Unfortunately, no postmortem ICD interroga-
tion could be obtained. Autopsy showed a well-placed ICD
electrode and no major organic pathology responsible for
death other than an enlarged and trabeculated RV. Histology
of the RV myocardium showed marked lipid inﬁltration and
ﬁbrosis in the anterior and lateral wall.
The pedigree elucidates a severe family history of SCD,
with a brother (III-5) who died suddenly and unexpected at
age 29; mother (II-2) and grandmother (I-2), at ages 62 and
37, respectively; and an uncle (II-3), who experienced SCD
at age 38 (Figure 1).
Also in this case, molecular genetic testing revealed the p.
Ser358Leu mutation in the TMEM43 gene, postmortem from
a sample of parafﬁn cuts. Subsequently, cascade screening
revealed the p.Ser358Leu TMEM43 mutation in 3 out of 4
living family members tested (Figure 1). Two of these (III-2,
III-3) exhibited signiﬁcant cardiopulmonary symptoms with
VF and several episodes of VT, and were treated with ICD.
At age 49, patient III-3 survived cardiac arrest owing to
external deﬁbrillation of VF after failure of appropriate
shocks from the ICD. Since then, amiodarone treatment kept
this patient in sinus rhythm. HTx was considered, but with
LV ejection fraction of 35% and stabilized heart rhythm HTx
has not been performed so far. Patient IV-1 is still young (19
years) and undergoes annual clinical monitoring.Case 3
A 33-year-old man with ARVC and ICD since the age of
24 years owing to numerous cases of nonsustained VT was
hospitalized after cardiac arrest. The patient collapsed in hishome with cardiac arrest and basic resuscitation was started
immediately (Table 1). Repeated shocks from the ICD
(Protecta XT DR; Medtronic, Minneapolis, MN) were
observed clinically before the paramedics arrived, and an
additional 12 external direct current shocks were delivered in
hospital owing to VF. Despite continued attempts at resusci-
tation, the patient died shortly after arriving at the hospital.
Two days prior to cardiac arrest, the patient had 2
episodes with signiﬁcant palpitations and was admitted
to hospital. ICD interrogation showed successful ATP
therapy of 2 episodes of fast monomorphic VT, all
parameters (sensing, threshold, impedance) remained
stable, and the patient was discharged the same day.
Unfortunately, no postmortem ICD recordings could be
retrieved. Medtronic found the ICD without any errors at
postmortem investigation. Previously, 3 VT ablation
procedures had been performed, the latest at age 28,
with apparent success and freedom from VT for several
years. Autopsy showed right-sided heart dilatation with a
well-placed ICD electrode. Several white, pale, and
yellow areas around the myocardium were observed,
corresponding to late changes with ﬁbrosis and ﬁbrofatty
replacement of the myocardium, as seen in most ARVC-5
patients. LV appeared unremarkable. Because the patient
was an adopted child from Sri Lanka, family history was
unknown.Molecular genetic analysis
In these 3 families DNA was puriﬁed from peripheral
leukocytes or parafﬁn cuts and used for Sanger sequencing
of all exons including exon–intron boundaries of the
TMEM43 gene. The p.Ser358Leu mutation (c.1073C4T,
NM_024334.2) was identiﬁed. Sanger sequencing was
performed using BigDye v1.1 (Applied Biosystems) and
Genetic Analyzer 3130XL (Applied Biosystems). None of
the family members had mutations in the desmosome genes
PKP2, DSG2, DSC2, DSP, and JUP, investigated with the
same principle. For detection of large genomic deletions or
insertions, multiplex ligation–dependent probe ampliﬁcation
was performed with the SALSA MLPA probemix P168-C1
ARVC-PKP2 (MRC Holland), which holds probes for exons
1–14 of PKP2; exons 1, 5, and 6 ofDSG2; exons 1, 7, and 17
of DSC2; exons 1, 5, 7, 9, 21, and 24 of DSP; and exons 2, 9,
and 17 of JUP. No large genomic rearrangements were
detected.Discussion
Three cases of SCD despite ICD treatment, within unrelated
families, suggest ARVC-5 to be even more serious than
expected. These cases indicate that patients with ARVC-5
are at especially high risk of SCD. The p.Ser358Leu
TMEM43 mutation was identiﬁed as an underlying cause,
with evidence of development of myocardial ﬁbrosis,
especially in the RV.
Figure 1 Pedigrees.
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of the myocardium by fatty and ﬁbrous tissue and myocardial
atrophy, predominantly in the RV, are progressing, and risk
of low-amplitude VF increases.9 From ICD interrogations,
under-sensed low-amplitude VF seems to be the reason why
long-term ARVC patients experience SCD without any ICD
therapy.9,10 This phenomenon may also play a role in our 3
index patients, although there was only 1 case in which we
had available ICD recordings that documented intermittent
under-sensed low-amplitude VF. Our patient histories alsosupport that failure of ICD therapy may be due to treatment-
refractory VF, likely because of severe progression in
myocardial ﬁbrosis. Another common electrocardiogram
abnormality is poor R-wave progression in the right pre-
cordial leads, predominantly observed in patients with
biventricular ARVC disease.11 To what extent the poor R-
wave progression is different in TMEM43 p.Ser358Leu
mutation–carrying ARVC-5 patients compared with other
ARVC patients remains unclear. In addition, the large
difference in age at death between index cases may still
Table 1 Key clinical ﬁndings
Case 1 Case 2 Case 3
Clinical Diagnosed at age 46 Diagnosed at age 27 Diagnosed at age 24
Dead at age 57 Dead at age 27 Dead at age 33
Episodes of VT Episodes of VT Episodes of VT, LVEF 50%
Heart failure with
dilated LV and LVEF
30%
No LV involvement, LVEF 65%
Endomyocardial RV
ﬁbrosis in 3-D maps
Medication ACE-I, metoprolol Sotalol Sotalol
Autopsy Not performed (family
refusal)
Enlarged trabeculated RV with lipid
inﬁltration and ﬁbrosis in anterior
and lateral wall
Right heart dilatation with ﬁbrosis and
ﬁbrofatty replacement of myocardium
in RV
Normal LV
2010 revised ARVC
criteria
Structural/functional
abnormalities in
echo/MRI
þþ -No MRI þþ
Tissue characteristics NA þþ –
Repolarization
abnormalities in ECG
– þþ þþ
Depolarization/
conduction
abnormalities in ECG
– – þþ
Ventricular arrhythmias þþ þþ þþ
Family history þþ þþ þþ
Fulﬁll criteria of ARVC Yes Yes Yes
þ ¼ minor criterion;þþ¼ major criterion.
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; ECG ¼ electrocardiogram; Echo ¼ echocardiogram; LV ¼ left ventricle; LVEF ¼ left ventricular
ejection fraction; MRI ¼ magnetic resonance imaging; NA ¼ not available; RV ¼ right ventricle; VT ¼ ventricular tachycardia.
Heart Rhythm Case Reports, Vol 2, No 3, May 2016220reﬂect a variable phenotypic clinical expression of ARVC,
even with this speciﬁc mutation.
Patients in 2 of our index cases underwent several catheter
ablations for monomorphic VT in order to obtain rhythm
control. A previous study suggests that catheter ablation may
be an effective tool in suppressing VT occurrence in the short
term but not effectively preventing VT recurrence over the
long term.12 The arrhythmia control by catheter ablation led
to an improvement in quality of life, but neither catheter
ablation nor ICD treatment improved the overall survival.12
However, results reported by Hodgkinson et al8 suggest a
beneﬁcial impact on survival, primarily in male ARVC-5
patients, with the use of ICD.
For most ARVC patients ICD prophylaxis is sufﬁcient
treatment. Nevertheless, ICD is not effective in preventing
SCD in all cases, and was not effective for the 3 ARVC-5
patients described. Despite signiﬁcant RV dysfunction, the
majority of ARVC patients are not considered for HTx
owing to relatively mild symptoms of heart failure. When
cardiac arrest occurs, the ICD can be unable to deﬁbrillate
these patients owing to treatment-refractory low-amplitude
VT or VF. The heart-transplanted patient in family 1, who
received a new heart owing to progressive heart failure andmultiple ICD shocks, is doing well 10 years later. The
optimal timing of HTx, however, has not been discussed.
Gilljam et al13 suggest consideration of HTx in patients with
repeated admissions to hospital with VF or VT, and
especially in RV-dysfunctional ARVC patients with
increased ﬁlling pressures, which corresponds to Fontan-
type physiology, which may be impossible to effectively
deﬁbrillate.Conclusion
Despite a fully functional ICD, patients with ARVC-5
caused by the TMEM43 p.Ser358Leu mutation may die of
SCD, which indicates an extremely severe phenotype. In the
future, prophylactic ICD as primary prevention of SCD
probably still will be the treatment of choice. However,
considering HTx for patients with ARVC-5 with impact on
RV and/or LV function and numerous episodes of VT/VF
could be next in line. This type of treatment already has been
demonstrated to have positive results, but further research is
needed for this to be incorporated in the treatment of severe
myocardial involvement in ARVC-5.
Figure 2 Electrocardiogram (ECG) and implantable cardioverter-deﬁbrillator (ICD) recordings. A: 12-lead ECG from index patient at age 42 in family 1. B:
Intermittent under-sensing of low-amplitude ventricular ﬁbrillation (VF). C: Appropriate ICD shock with conversion of VF to short-lasting sinus rhythm and
recurrent slow ventricular tachycardia.
221Aalbæk Kjærgaard et al Failure of ICD Therapy in ARVC-5 PatientsAcknowledgments
The authors thank Sonja Runge, CCDS, Department of Cardiol-
ogy, Aarhus University Hospital, for providing ICD recordings.References
1. Merner ND, Hodgkinson KA, Haywood AF, et al. Arrhythmogenic right
ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder
caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 2008;82
(4):809–821.
2. Hodgkinson KA, Connors SP, Merner N, Haywood A, Young T-L, McKenna
WJ, Gallagher B, Curtis F, Bassett AS, Parfrey PS. The natural history of a
genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a
p.S358L mutation in TMEM43. Clin Genet 2013;83(4):321–331.3. Groeneweg JA, van der Heijden JF, Dooijes D, van Veen TA, van Tintelen JP,
Hauer RN. Arrhythmogenic cardiomyopathy: diagnosis, genetic background, and
risk management. Neth Heart J 2014;22(7-8):316–325.
4. Milting H, Klauke B, Christensen AH, et al. The TMEM43 Newfoundland
mutation p.S358L causing ARVC-5 was imported from Europe and increases the
stiffness of the cell nucleus. Eur Heart J 2014:872–881.
5. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right
ventricular cardiomyopathy/dysplasia: proposed modiﬁcation of the Task Force
Criteria. Eur Heart J 2010;31(7):806–814.
6. Christensen A, Andersen C, Tybjærg-Hansen A, Haunso S, Svendsen J.
Mutation analysis and evaluation of the cardiac localization of TMEM43
in arrhythmogenic right ventricular cardiomyopathy. Clin Genet 2011;80:
256–264.
7. Rajkumar R, Sembrat JC, McDonough B, Seidman CE, Ahmad F.
Functional effects of the TMEM43 Ser358Leu mutation in the pathogenesis of
arrhythmogenic right ventricular cardiomyopathy. BMC Med Genet 2012;
13(1):21.
Heart Rhythm Case Reports, Vol 2, No 3, May 20162228. Hodgkinson KA, Parfrey PS, Bassett AS, Kupprion C, Drenckhahn J,
Norman MW, Thierfelder L, Stuckless SN, Dicks EL, McKenna WJ, Connors
SP. The impact of implantable cardioverter-deﬁbrillator therapy on survival in
autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5).
J Am Coll Cardiol 2005;45(3):400–408.
9. Basso C, Corrado D, Bauce B, Thiene G. Arrhythmogenic right ventricular
cardiomyopathy. Circ Arrhythm Electrophysiol 2012;5(6):1233–1246.
10. Watanabe H, Chinushi M, Izumi D, Sato A, Okada S, Okamura K, Komura S,
Hosaka Y, Furoshima H, Washizuka T, Aizawa Y. Decrease in amplitude of
intracardiac ventricular electrogram and inappropriate therapy in patients with an
implantable cardioverter deﬁbrillator. Int Heart J 2006;47:363–370.11. Steriotis AK, Bauce B, Daliento L, Rigato I, Mazzotti E, Folino AF,
Marra MP, Brugnaro L, Nava N. Electrocardiographic pattern in arrhy-
thmogenic right ventricular cardiomyopathy. Am J Cardiol 2009;103(9):
1302–1308.
12. Komura M, Suzuki J-I, Adachi S, et al. Clinical course of arrhythmogenic
right ventricular cardiomyopathy in the era of implantable cardioverter-
deﬁbrillators and radiofrequency catheter ablation. Int Heart J 2010;51(1):
34–40.
13. Gilljam T, Bergh C-H. Right ventricular cardiomyopathy: timing of heart
transplantation in Uhl’s anomaly and arrythmogenic right ventricular cardiomy-
opathy. Eur J Heart Fail 2009;11(1):106–109.
